754-5 A Multi-Centre Double Blind Crossover Comparison of Disopyramide, Atenolol, and Placebo for Symptomatic Paroxysmal Atrial Fibrillation  by Murgatroyd, Francis D. et al.
JACC February 1995 ABSTRACfS 231A
Abel E. Moreyra, Alan C. Wilson, Patrice C. Gregory, John B. Kostis, MIDAS.
UMONJ-Robert Wood Johnson Medical School, New BrunswiCk, NJ
2:00
1755-1 1 Early Angioplasty During Hospitalization for Acute
Myocardial Infarction Improves 3-Year Survival
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There was a trend to a decrease in LA-EV and LA-FV post-conversion to
NSR (p < 0.05 for group 1 and all pts combined). The left ventricular ejec-
tion fractions pre-ECV were not significantly different between groups (55 ±
11 % vs 46 ± 9%, P = NS). Spontaneous contrast was present in 6 pts in
group 1 (86%) and 4 pts in group 2 (44%) at baseline and worsened in 1 pt in
group 1 (14%) and 3 pts in group 2 (33%) only after conversion to NSR. One
pt in group 1 and 3 pts in group 2 had no spontaneous contrast at baseline
and developed it only after conversion to NSR. In conclusion: 1) Decreased
left atrial mechanical function occurs after conversion to NSR. 2) Left atrial
mechanical function is not significantly decreased after ineffective ECV at-
tempts. 3) Spontaneous contrast was found more often in pts requiring less
energy for cardioversion. 4) Spontaneous contrast worsened more often in
pts requiring more energy for conversion to NSR and worsened only after
conversion to NSR. 5) These findings suggest that left atrial "stunning" and
worsening stasis of flow is due to conversion to NSR and not secondary to
ineffective ECV attempts.
We studied the effect on survival of PTCA during hospitalization for acute
myocardial infarction (MI) in 42,595 patients from the MIDAS registry in New
Jersey (years 1986-87). The 3-year unadjusted death rate was high, 36.0%
in the absence of PTCA, but much lower, only 8.7%, in the 684 patients un-
dergoing PTCA [7.7% (40/508) in men, and 11.7% (21/176) in women]. Early
revascularization (PTCA in first 24 hours after admission) was performed in
41 % of the patients. Multivariate Cox proportional hazards regression anal-
ysis was performed, including previously reported predictors of death fol-
lowing PTCA such as female sex, advanced age, impaired left ventricular
function and prior MI, along with variables describing co-morbidity, race and
insurance coverage. The adjusted death rate ratios (RR, 95% C.I.) associated
with performance of early or late PTCA are noted below.
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developed nonsustained PVT during or shortly after the infusion (11 of 15
occurred during the first infusion).
Conclusions: Ibutilide given in repeated doses is highly effective compared
to placebo in rapidly terminating chronic atrial fibrillation or flutter and un-
der monitored conditions is a potential alternative to currently available car-
dioversion options.
Continuous Transesophageal Echocardiography
During Sequential Electrical Cardioversion Attempts
for Atrial Fibrillation: Effect on Left Atrial Appendage
Function and Spontaneous Contrast Formation
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1754-51 A Multi-Centre Double Blind Crossover Comparison
of Disopyramide, Atenolol, and Placebo for
Symptomatic Paroxysmal Atrial Fibrillation
Francis D. Murgatroyd, Dympna M. O'Farrell, John P. Foran, Stephen J. Kelly, David
E. Ward, A. John Camm, Controlled Randomized Atrial Fibrillation Trial
Investigators. St George's Hospital Medical School, London UK
Class la drugs and II-blockers are commonly used to treat symptomatic
paroxysmal atrial fibrillation (PAF), and patients with "vagal" and "adrener-
gic" patterns of PAF onset are held to respond to anticholinergic and fJ-
blocking agents, respectively. However, neither class has been subjected to
controlled clinical trials in this condition. CRAFT-2 was a double blind three-
way crossover comparison of atenolol (At) (initial dose 100 mg daily). disopy-
ramide (Dp) (initial dose 450 mg daily), and matched placebo (PI). The primary
endpoint was the time to the first and second attacks of PAF, documented by
transtelephonic monitoring, with a maximum of two attacks or two months
on each treatment. All patients completed a 1O-item symptom questionnaire
aimed at identifying vagal and adrenergic patterns of arrhythmia onset.
75 patients from 7 hospitals were screened for CRAFT-2, and 30 were
randomized; their clinical characteristics closely approximated those of 334
patients with PAF in the CRAFT registry. The numbers of patients with 0 and
<2 attacks on placebo were 0, and 1, respectively. On At, these were 6 and
7, and on Dp 5 and 6, respectively. The median times to the first and second
attack were 4.2 and 7.5 days on PI, 4.4 (p = 0.08) and 16.4 (p = 0.031 days on
Dp, and 12.4 (p ~ 0.007) and 29.1 (p = 0.008) days on At, respectively. The
mean (SO) heart rates during attacks were 130 (21) beatslmin on PI, 135 (26)
on Dp. (p = NS), and 115 (23) on At Ip = 0.02). Dose reductions due to side-
effects were required in 0, 2, and 4 cases, and treatment withdrawal was
required in 0, 1, and 1 cases during PI. Dp, and At treatment, respectively.
There was no clear relationship between autonomic patterns of symptom
onset and the response to treatment.
We conclude that disopyramide and especially atenolol reduce the fre-
quency of symptomatic episodes of PAF. The efficacy of atenolol may relate
to symptom reduction because of a lower heart rate, but that of disopyra-
mide is likely to be a true antiarrhythmic action. The pattern of symptom
onset does not easily predict response to individual antiarrhythmic agents.
Rita A. Falcone, Fred Morady, William F. Armstrong. University of Michigan, Ann
Arbor. MI
Electrical cardioversion (ECV) of atrial fibrillation to normal sinus rhythm
(NSR) is associated with an increased risk of stroke presumably from left
atrial mechanical "stunning" and subsequent stasis of blood. The effect of
ineffective electrical shocks on the mechanical function of the left atrium and
the formation or worsening of spontaneous contrast is unknown. We stud-
ied 16 pts with atrial fibrillation (>2 days) pre and post each ECV attempt
during continuous transesophageal echocardiography. ECV was performed
at 50, 100,200, then 360J until NSR was achieved. Group 1 (N = 7) required
50J and group 2 (N = 9) >50J for conversion to NSR. Left atrial appendage
emptying (LA-EV) and filling velocities (LA-FV) were measured (m/sec) with
pulsed wave Doppler and spontaneous contrast was graded visually pre- and
post- each ECV attempt.
LA-EV
pre 50J 100J NSR
all pts 0.41 ± 0.12 0.28 ± 0.16'
grp 1 0.42 ± 0.11 0.25 ± 015" 0.25 ± 0.15'
grp 2 0.40± 0.14 0.36 ± 0.15 0.60 ± 0.23 0.28 ± 0.17
LA-FV
pre 50J 100J NSR
all pts 0.47±0.18 0.33 ± 0.14'
grp 1 0.44 ± 0.08 0.30 ± 0.15'
--* 0.30 ± 0.15'
grp 2 0.47 ± 0.23 0.42±0.15 0.39 ± 0.16 0.33 ± 0.15
, pre vs NSR. p < 0.05
ConClusion: Early PTCA during hospitalization for acute MI is indepen-
dently associated with a 50% reduction in 3-year death risk in the middle-age
and oldest groups after controlling for all the other factors in the Cox model.
The benefit is also observed with late PTCA, but only achieves statistical sig-
nificance in the oldest group.
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Despite clear benefit of thrombolysis (Tlysis) and primary (1 ') PTCA for acute
MI, prior reports have indicated a low use of thrombolytic therapy in the U.S.
Further, single center reports have suggested that mortality is up to 5 times
higher when thrombolysis is not given. To evaluate the management and
outcome of acute MI in 1994, we conducted a registry in 20 hospitals (16
with l' PTCA capability) and prospectively identified all consecutive patients
(ptsl presenting with acute MI and ST segment elevation or new LBBB. A
total of 587 pts were identified, 200 were enrolled in the TIM I 9 thrombolytic
trial of hirudin vs. heparin, and 387 in the TIMI 9 Registry. Tlysis was given
to 356 of 587 (60.7%) pts (of whom 200/356 (56%) were enrolled in TIMI
9); l' PTCA was performed in 62/587 (10.5%) of the total population and
medical therapy used in 169/587128.8%). Of the patients enrolled in the TIMI
9 Registry, those treated with l' PTCA were significantly younger, 60.7 years,
